<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00117767</url>
  </required_header>
  <id_info>
    <org_study_id>CSFO327C2301</org_study_id>
    <nct_id>NCT00117767</nct_id>
  </id_info>
  <brief_title>Terbinafine Compared to Griseofulvin in Children With Tinea Capitis</brief_title>
  <official_title>Efficacy and Safety of Terbinafine Compared to Griseofulvin in Children With Tinea Capitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Tinea capitis is a dermatophyte infection of the scalp hair follicles, which occurs primarily
      in children. Hair loss, hair breakage, scaling, plus various degrees of erythema, pustules
      and pruritus are the primary clinical signs which can be associated with tinea capitis. The
      infection is caused by a relatively small group of dermatophytes in the genera Trichophyton
      and Microsporum.

      Terbinafine hydrochloride is a synthetic allylamine derivative antifungal agent. This study
      will evaluate the efficacy and safety of terbinafine in children with tinea capitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete cure (negative mycology and clinical cure) rate at Week 10</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical cure rate at Week 10</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mycological cure rate at Week 10</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of terbinafine</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment>720</enrollment>
  <condition>Tinea Capitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Terbinafine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Griseofulvin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terbinafine hydrochloride (HCl)</intervention_name>
    <description>Terbinafine hydrochloride (HCl) pediatric formulation (minitablets)o.d. administration</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Lamisil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Griseofulvin</intervention_name>
    <description>Griseofulvin pediatric suspension o.d. administration</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Grilfulvin V</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with clinical diagnosis of tinea capitis confirmed by positive KOH determined
             by the central mycology laboratory.

          -  Male or female patients who are at least 4 years old and no more than 12 years old.

        Exclusion Criteria:

          -  Patients having a medical condition that alters the absorption and/or metabolism of
             terbinafine (e.g. liver, renal disease etc.)

          -  Patients receiving medication that may interfere with the evaluation of the drug's
             effect

          -  Patients who have kerions requiring immediate treatment or treatment with systemic
             corticosteroids and/or systemic antibiotics

          -  Patients with a history of liver disease or current/active liver disease or with
             elevation of livery enzymes outside of the normal range corresponding to their age

          -  Patients who have received recent systemic or topical treatment for tinea capitis
             within the specified time periods (e.g. systemic antifungals within 2 months of
             screening visit, topical treatments [e.g. antifungals, corticosteroid preparations,
             zinc pyrithione or selenium sulfide or tar containing products] within 1 week of
             screening).

          -  Patients with a history of systemic lupus erythematosus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Pharmaceuticals</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <zip>07936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2293</url>
    <description>Results available for CSFO327C2301 at Novartis Clinical Trials Database</description>
  </link>
  <reference>
    <citation>Elewski BE, CÃ¡ceres HW, DeLeon L, El Shimy S, Hunter JA, Korotkiy N, Rachesky IJ, Sanchez-Bal V, Todd G, Wraith L, Cai B, Tavakkol A, Bakshi R, Nyirady J, Friedlander SF. Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials. J Am Acad Dermatol. 2008 Jul;59(1):41-54. doi: 10.1016/j.jaad.2008.02.019. Epub 2008 Apr 18.</citation>
    <PMID>18378354</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>June 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2005</study_first_posted>
  <last_update_submitted>May 28, 2017</last_update_submitted>
  <last_update_submitted_qc>May 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Terbinafine, Tinea capitis, pediatric, antifungal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea</mesh_term>
    <mesh_term>Tinea Capitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terbinafine</mesh_term>
    <mesh_term>Griseofulvin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

